Apyx Medical Corp (APYX)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
$3.05-0.33%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
QuarterlyIQ Insights · APYX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -49.0% |
| Our one-year growth estimate | diamond | 9.7% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 58.7 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 8 industry peers · Company calendar date is not available
APYX — earnings miss
Dated 2026-08-06
Results of Operations and Financial Condition On August 6, 2026, Apyx Medical Corporation (the "Company") issued a press release reporting on its results of operations for the second quarter ended June 30, 2026. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. This information is intended to be furnished under
Why it matters: Higher expenses could hurt profits and make investors feel negative.
Worry ifOperating costs are under $45 million for FY2026.
Less concerning ifOperating costs are over $45 million for FY2026.
Why it matters: Higher costs could slow down efforts to cut losses and make more money.
Worry ifOperating costs were under $11 million for Q3 2026.
Less concerning ifOperating costs are over $11 million for Q3 2026.
Why it matters: Successful rollout of this new feature could enhance market demand and drive revenue growth.
Supportive ifManagement says at least 10 key surgeons will adopt the product next quarter.
Worry ifFew surgeons use the power liposuction feature. There are less than 5 key users.
Why it matters: Updates from the new Executive Chairman could signal changes in strategy or direction. This could impact future growth.
Watch forThe company shares new plans led by the Executive Chairman.
Also watch forNo new plans are shared after the appointment.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$246 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $649 loss on $10,000 · 6.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,848 loss on $10,000 · 38.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Good clinical results could help Apyx's market position. This may lead to more product use.
Supportive ifWatch for new clinical data. It may show better results in treating cellulite with Avéli and Renuvion.
Worry ifBad clinical results or no new data on cellulite treatment.
Why it matters: Better operating income means better cost management. This leads to more profit.
Supportive ifOperating income is positive and stays above $500,000 for the next quarter.
Worry ifOperating income stays negative or gets worse in the next quarter.
Why it matters: Less loss would show better financial health and efficiency.
Supportive ifOperating loss for Q3 2026 was less than $2 million.
Worry ifOperating loss remains above $2 million for Q3 2026.
Why it matters: Good clinical results could show the product works and increase sales in aesthetics.
Supportive ifA new study shows at least 75% of patients see improvement in cellulite.
Worry ifData shows less than 60% of patients see improvement in cellulite.
Why it matters: Better operating income shows the company is managing costs well. This can help investor trust.
Supportive ifOperating income turns positive or gets better from -$911,000 in Q1 2026.
Worry ifOperating income stays negative or gets worse in Q2 2026.
Why it matters: Positive cash flow from operations is vital for financial health. It shows the company can survive without extra money.
Supportive ifCash from operations turns positive in Q2 2026.
Worry ifCash from operations remains negative in Q2 2026.
Why it matters: The company raised its FY2026 revenue guidance. Confirmation shows strong demand for products.
Supportive ifQ2 revenue guidance confirmed or raised above $59 million during the earnings call.
Worry ifQ2 revenue guidance lowered below $59 million during the earnings call.
Why it matters: If sector growth speeds up, Apyx could do better. This may improve its outlook.
Supportive ifHealth Care sector revenue growth exceeds 10% year over year.
Worry ifSector revenue growth remains below 10% year over year.
Why it matters: Earnings results will show if the company can meet or exceed expectations. This impacts investor sentiment.
Watch forQ2 earnings are much better than analyst expectations.
Also watch forQ2 earnings fall short of analyst expectations.
Why it matters: An increase in revenue guidance shows management's confidence in growth. It could signal better performance ahead.
Supportive ifManagement raises total revenue guidance to over $60M for FY2026.
Worry ifManagement keeps revenue guidance at or below $59M for FY2026.
Why it matters: Growth in South Korea may show more international demand for Apyx products.
Supportive ifInternational sales in South Korea are over $2 million in the next quarter.
Worry ifInternational sales in South Korea fall below $1 million in the next quarter.
Why it matters: Strong growth in this segment indicates demand for AYON and Renuvion products. It helps confirm management's revenue guidance for FY2026.
Supportive ifSurgical Aesthetics revenue growth exceeds 25% year over year in Q3 2026.
Worry ifSurgical Aesthetics revenue growth falls below 20% year over year in Q3 2026.
Why it matters: Positive feedback would help AYON succeed. It would also support management's plan. This is important for growing market presence.
Supportive ifFDA gives good feedback or approval for more use of AYON's power liposuction.
Worry ifFDA raises concerns or delays the rollout of AYON's power liposuction.